Back to Authors

Hill, Brian T.

https://orcid.org/0000-0001-8781-3327

A5006235077 | I1316902750

Mayo Clinic

Cleveland Clinic

Citations 87

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1328-1331

10.1182/blood-2022-157829

Outcomes of DLBCL Patients Achieving Complete Remission after R-ICE Chemoimmunotherapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 381-383

10.1182/blood-2022-170752

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7454-7456

10.1182/blood-2022-167868

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4657-4660

10.1182/blood-2022-170486

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1852-1855

10.1182/blood-2022-162421

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10391-10393

10.1182/blood-2022-159725

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7512-7515

10.1182/blood-2022-155603

Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 13180-13181

10.1182/blood-2022-167959

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1042-1043

10.1097/01.hs9.0000847488.86807.da

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

Journal of the National Comprehensive Cancer Network | June 17, 2022 | Volume: 20 | Issue: 6 | Pages: 622-634

10.6004/jnccn.2022.0031 | PMID 35714675

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.